🇺🇸 FDA
Pipeline program

Epidyolex 100 mg/ml oral solution

GWEP17005

Phase 3 small_molecule active

Quick answer

Epidyolex 100 mg/ml oral solution for Dravet Syndrome, Tuberous sclerosis complex, Lennox-Gastaut Syndrome is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Dravet Syndrome, Tuberous sclerosis complex, Lennox-Gastaut Syndrome
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials